Entrada Therapeutics, Inc. (TRDA) earnings
TRDA earnings moved a median of +2.21% by the close. Quarterly and annual TRDA reports and results, each read against the price at its own news timestamp. Back to the TRDA overview →
21 measured TRDA earnings events.
Where these TRDA earnings landedvs 21 measured TRDA earnings reactions
| Middle 50% of TRDA earnings reactions | +0.44% to +5.13% |
|---|---|
| Median reaction (to close) | +2.21% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 TRDA earnings events with a measured close landed between +0.44% and +5.13%; 76% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Entrada Therapeutics Reports Second Quarter 2026 Financial Results | Press release | -3.08% | -5.49% | |
| Form 10-Q Entrada Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.08% | -5.49% | |
| Entrada Therapeutics Reports First Quarter 2026 Financial Results | Press release | -14.81% | +0.44% | |
| Form 10-Q Entrada Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -14.81% | +0.44% | |
| Form 10-K Entrada Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.09% | +10.35% | |
| Entrada Therapeutics Reports Third Quarter 2025 Financial Results | Press release | -1.84% | +2.21% | |
| Form 10-Q Entrada Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.84% | +2.21% | |
| Entrada Therapeutics Reports Second Quarter 2025 Financial Results | Press release | -1.24% | +4.94% | |
| Form 10-Q Entrada Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.24% | +4.94% | |
| Entrada Therapeutics Reports First Quarter 2025 Financial Results | Press release | +4.63% | +6.42% | |
| Form 10-Q Entrada Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +4.63% | +6.42% | |
| Form 10-K Entrada Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.37% | -1.88% | |
| Entrada Therapeutics Reports Third Quarter 2024 Financial Results | Press release | -2.77% | +3.16% | |
| Form 10-Q Entrada Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.77% | +3.16% | |
| Entrada Therapeutics Reports Second Quarter 2024 Financial Results | Press release | -7.83% | -0.75% | |
| Form 10-Q Entrada Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -7.83% | -0.75% | |
| Entrada Therapeutics Reports First Quarter 2024 Financial Results | Press release | +0.07% | +0.65% | |
| Form 10-Q Entrada Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.07% | +0.65% | |
| Form 10-K Entrada Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.16% | +5.13% | |
| Entrada Therapeutics Reports Third Quarter 2023 Financial Results | Press release | +0.00% | +5.46% | |
| Form 10-Q Entrada Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +5.46% |
Keep exploring
More TRDA: analyst actions → · SEC filings → · TRDA overview →